Clinical Trial Update: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

This phase 2 clinical trial update describes two regimens for newly diagnosed multiple myeloma: daratumumab with ixazomib and dexamethasone, or daratumumab with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)
• Ixazomib (Ninlaro) (Ixazomib)

Snippet

Sponsor: Emory University | Conditions: Plasma Cell Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING